Incyte analyst coverage
WebApr 11, 2024 · According to analysts' consensus price target of $85.43, Incyte has a forecasted upside of 15.5% from its current price of $73.94. Amount of Analyst Coverage Incyte has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. WebAug 30, 2024 · Get the latest Incyte Corporation (INCY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ... News Profile Analyst Coverage 5 Yr.
Incyte analyst coverage
Did you know?
WebApr 4, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million during the quarter, compared to analyst estimates of $880.25 million. During the same period last year, the business earned ($0.07) EPS. Incyte's quarterly revenue was up 7.4% compared to the same quarter last year. WebApr 12, 2024 · -- Incyte has an average outperform rating and price target range of $61 to $118, according to analysts polled by Capital IQ. Price: 74.54, Change: +0.37, Percent Change: +0.50 ... April 12, 2024 ... Rankings Coverage. Screeners Stock Screener Home. Investment Themes. Ageing Population. Sin stocks. The SPAC ...
Web2 days ago · Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $87.46, which is a 17.7% upside from current levels. In a report issued on April 10, RBC Capital also downgraded ... WebApr 12, 2024 · Over the past twelve months, analysts' opinions have been revised negatively. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity. The price targets of analysts who cover the stock differ significantly.
WebApr 10, 2024 · Incyte Stock (NASDAQ:INCY), Analyst Ratings, Price Targets, Predictions Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can... WebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00.
WebMar 25, 2024 · StockNews.com assumed coverage on Incyte in a report on Thursday, March 16th. They set a "strong-buy" rating on the stock. ... The company had revenue of $926.70 million for the quarter, compared to analyst estimates of $880.25 million. Incyte had a return on equity of 11.45% and a net margin of 10.03%. The business's revenue was up 7.4% on a …
WebIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages,... cumberland soar for funWebApr 10, 2024 · The latest price target for . Incyte (NASDAQ: INCY) was reported by RBC Capital on April 10, 2024.The analyst firm set a price target for $79.00 expecting INCY to rise to within 12 months (a ... east texas auto theft task forceWebApr 10, 2024 · Analyst coverage for Incyte stock is good. Key information 29.0% Earnings growth rate 28.0% EPS growth rate Recent future growth updates Aug 03 Aug 03 First quarter 2024 earnings: EPS and revenues miss analyst expectations May 03 Show all updates Earnings and Revenue Growth Forecasts Show more Analyst Future Growth … cumberland smilesWebDec 29, 2024 · Incyte ( NASDAQ: INCY) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EPS growth estimates... east texas asphalt in center texasWebJan 9, 2024 · JP MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2024. Forward-looking statements. Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding 2024 newsflow items; the … cumberlands ne lonWebFeb 9, 2024 · These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months. east texas automotive hawkins txWebFeb 22, 2024 · Plaintiff Novartis Pharma AG ("Novartis") and Defendant Incyte Corporation ("Incyte") forged an agreement to work together to commercialize a valuable drug compound called ruxolitinib. Incyte had an innovative concept. Novartis provided financing to kickstart its development, and contributed Novartis's global reach and marketing expertise. east texas asphalt livingston tx